May 2024 – Page 13

Lilly, Novo Nordisk, weekly insulin, primary endpoint, pivotal trials, diabetes management, insulin therapy, clinical trials, diabetes treatment, pharmaceutical industry.

Galapagos Expands Decentralized CAR-T Manufacturing Across the Nation with Strategic Partnership

12 months ago talkbio0Tagged Biotechnology, Cancer Therapeutic Procedure, CAR-T, decentralized, expansion, Galapagos, healthcare innovation, Immunotherapy, Manufacture, nationwide, Partnership

Galapagos, decentralized CAR-T manufacturing, partnership, nationwide expansion, cancer treatment, immunotherapy, biotechnology, healthcare innovation.

Johnson & Johnson Expands into IL-13 and TSLP Market with Strategic Acquisition

12 months ago talkbio0Tagged Acquisition (action), Biological Factors, competition, Drug Industry, expansion, I&I, Inflammatory disorder, Interleukin-13, Johnson and Johnson, Market, strategic, TSLP gene

Johnson & Johnson, I&I acquisition, IL-13, TSLP, competitive market, strategic expansion, pharmaceutical industry, biologics, inflammatory diseases.

ICER Raises Concerns Over Uncertainties in Lykos MDMA Clinical Trials Ahead of FDA Advisory Committee Meeting

12 months ago talkbio0Tagged AdComm, Advisory Committees, Clinical Trials, CREM gene, Lykos ', Midomafetamine, Uncertainty, United States Food and Drug Administration

ICER, Lykos, MDMA, clinical trials, uncertainties, FDA, AdComm, advisory committee meeting

Ascendis Hormone Replacement Therapy Faces Setback with FDA Review Extension

12 months ago talkbio0Tagged Ascendis Pharma, Extension, Hormones, Replacement therapy, Review [Publication Type], three-month, United States Food and Drug Administration

Ascendis Pharma, hormone replacement therapy, FDA review, delay, three-month extension.

Revolutionizing Protein Design: Nabla Bio Secures $26M for AI-Driven Pharmaceutical Solutions

12 months ago talkbio0Tagged Artificial Intelligence, Biotechnology, Drug Discovery, genAI protein design, healthcare innovation, Nabla Bio, pharmaceutical partners, Protein Engineering

Nabla Bio, genAI protein design, funding, pharmaceutical partners, biotechnology, protein engineering, drug discovery, artificial intelligence, healthcare innovation.

FDA Rejects Hepatitis B Vaccine Update Due to Inadequate Documentation and Data

12 months ago talkbio0Tagged Destructive procedure (surgical), Documents, hepatitis B surface antigen vaccine, Inadequate (qualifier), Rejection (Psychology), United States Food and Drug Administration, Vaccines

FDA, hepatitis B vaccine, vaccine update, document destruction, insufficient data, rejection